Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with or without leuprolide versus placebo plus leuprolide in high-risk nonmetastatic prostate cancer after definitive therapy
2024-513521-23-00Phase 3Authorised
- Sponsor
- Medivation
- Start
- Jul 2024
- Modality
- Small Molecules, Peptides
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Enzalutamide plus leuprolide, Enzalutamide monotherapy and Placebo plus leuprolide (3 arms). Primary endpoint: Metastasis-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
enzalutamideleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-513521-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513521-23-00.